mercredi 19 avril 2017

Onco Actu du 19 avril 2017

1. Biologie

This tech was meant to explore space. Can it also solve the mysteries of breast cancer? [STAT]

1.1 Biologie - Gènes

Missing Genes Point to Possible Drug Targets [NIH Director's blog]

2.5 Etiologie - Gènes

Discovering unknown causes of cancer through ‘fingerprints’ in DNA [Cancer Research UK]

5. Traitements

Targeting cancer spread: keeping breast tumours under LOX and key [Cancer Research UK]

Precision Medicine Pioneer Targets Earlier Cancer Detection [Medscape]

5.12.2 Immunothérapies - CAR-T

Novartis gets second CAR-T candidate FDA ‘breakthrough’ tag [FierceBiotech]

Novartis Snags Coveted FDA 'Breakthrough' Label for CAR-T, Trial Results Still Under Wraps [The Street]

Novartis is keeping JULIET in hiding, but the FDA takes a peek and hands over a ‘breakthrough’ title [EndPoints]

5.12.5 Immunothérapies - Pharma

Ex-Dendreon CEO, Gold, Returns to Wall Street as Alpine, Nivalis Merge [Xconomy]

Former Dendreon CEO Mitch Gold Returns to Public Biotech Stage with Cancer Immunotherapy Merger [The Street]

5.2 Pharma

Puma Biotechnology Announces FDA Advisory Committee to Review Neratinib for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer [Puma]

Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug [The Street]

5.2.1 Pharma - Partenariats

CRT pioneer fund, Cancer Research UK and NCI collaborate to boost research against the ‘undruggable’ RAS [Cancer Research UK]

5.2.3 Pharma - économie

Hey Pfizer, Novartis and Eli Lilly. G1 Therapeutics says it can beat all of you in its $115M IPO [EndPoints]

5.3.4 Traitements - AMM (FDA, EMA)

FDA grants Roche’s TECENTRIQ® (atezolizumab) accelerated approval as initial treatment for certain people with advanced bladder cancer [Roche]

5.4 Traitements - Economie

James Raftery: NICE’s proposed new QALY modifier for appraising highly specialised technologies [BMJ Blogs]

6.10.1 Politiques (USA)

Federal biomedical science policy under Donald Trump, nearly 100 days in [Respectful Insolence]